artesunic acid has been researched along with Breast Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bindra, AK; Chen, X; Guo, Y; He, IW; Jana, D; Liu, J; Qian, C; Wang, D; Wu, Y; Zhang, X; Zhao, Y | 1 |
| Drif, AI; Efferth, T; Saeed, MEM | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
| Ghafouri, H; Majidi, M; Pirali, M; Taheri, M; Zarei, S | 1 |
| Edler, L; Efferth, T; Elsässer, M; Goeckenjan, M; Munzinger, J; Osburg, J; Remppis, BA; Schneeweiss, A; Sertel, S; Storch-Hagenlocher, B; Strowitzki, T; von Hagens, C; Walter-Sack, I | 1 |
| Kim, JO; Nguyen, CN; Nguyen, HT; Tran, BN; Yong, CS | 1 |
| Chockalingam, S; Ghosh, SS; Ghoshal, A; Raza, A | 1 |
| Liu, L; Wei, F; Wen, L; Yu, T | 1 |
| Guo, Y; Guo, Z; Wang, K; Wang, X; Yuan, H; Zhang, S | 1 |
| Fernando, W; Greenshields, AL; Hoskin, DW | 1 |
| Edler, L; Efferth, T; Elsässer, M; Goeckenjan, M; Munzinger, J; Remppis, BA; Schneeweiss, A; Sertel, S; Storch-Hagenlocher, B; Strowitzki, T; von Hagens, C; Walter-Sack, I | 1 |
| Chen, K; Duan, WM; Li, W; Lin, F; Shou, LM; Tao, M; Wu, MY; Xie, X; Xie, YF | 1 |
| Äbelö, A; Ashton, M; Blank, A; Ericsson, T; von Hagens, C | 1 |
| Kim, JO; Nguyen, CN; Nguyen, HT; Nguyen, TD; Poudel, BK; Tran, TH; Yong, CS | 1 |
| Firestone, GL; Hargraves, KG; He, L | 1 |
| Kim, JO; Nguyen, AN; Nguyen, CN; Tran, TH; Yong, CS | 1 |
| Baumann, I; Edler, L; Hoth, S; König, M; Sertel, S; von Hagens, C; Walter-Sack, I | 1 |
| Dalgleish, AG; Gravett, AM; Liu, WM | 1 |
| Brady, NR; Efferth, T; Eils, R; Hamacher-Brady, A; Jennewein, N; Mora, R; Stein, HA; Toegel, I; Turschner, S | 1 |
| Bachmeier, B; Efferth, T; Fichtner, I; Killian, PH; Kronski, E; Pfeffer, U | 1 |
4 trial(s) available for artesunic acid and Breast Neoplasms
| Article | Year |
|---|---|
Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2017 |
Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).
Topics: Administration, Oral; Adult; Aged; Artesunate; Breast Neoplasms; Compassionate Use Trials; Creatinine; Female; Humans; Liver; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome | 2019 |
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimalarials; Artemisinins; Artesunate; Breast Neoplasms; Female; Humans; Intestinal Absorption; Middle Aged; Models, Biological; Saliva | 2014 |
Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Audiometry; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome; Vertigo | 2016 |
16 other study(ies) available for artesunic acid and Breast Neoplasms
| Article | Year |
|---|---|
Missing-Linker-Assisted Artesunate Delivery by Metal-Organic Frameworks for Synergistic Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Artesunate; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Carriers; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Metal-Organic Frameworks; Mice; Photosensitizing Agents; Reactive Oxygen Species | 2021 |
Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
Topics: Artesunate; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Female; Humans; Molecular Docking Simulation | 2022 |
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Topics: Adenosine Diphosphate; Antimalarials; Antineoplastic Agents; Artesunate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benztropine; Breast Neoplasms; Cell Line, Tumor; Chloroquine; Colonic Neoplasms; Containment of Biohazards; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Fluoxetine; Fluphenazine; Humans; Ki-67 Antigen; MCF-7 Cells; Michigan; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Sertraline; Thioridazine | 2022 |
Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells.
Topics: Adenosine Triphosphatases; Apoptosis; Artesunate; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Female; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2 | 2020 |
Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Lactic Acid; Nanoparticles; Paclitaxel; Polyglycolic Acid | 2017 |
Connexin-43 enhances tumor suppressing activity of artesunate via gap junction-dependent as well as independent pathways in human breast cancer cells.
Topics: Antineoplastic Agents; Artesunate; Breast Neoplasms; Cell Survival; Connexin 43; DNA Damage; Gap Junctions; Humans; Inhibitory Concentration 50; MCF-7 Cells; Models, Biological; Reactive Oxygen Species | 2017 |
Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.
Topics: Antineoplastic Agents; Artesunate; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Proliferation; DNA Damage; Dose-Response Relationship, Drug; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Phosphorylation | 2018 |
Towards rational design of RAD51-targeting prodrugs: platinum
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Drug Design; Female; Humans; Molecular Targeted Therapy; Organoplatinum Compounds; Ovarian Neoplasms; Prodrugs; Rad51 Recombinase | 2018 |
The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Artesunate; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Humans; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2019 |
Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Artemisinins; Artesunate; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epirubicin; Female; G2 Phase Cell Cycle Checkpoints; Humans; Membrane Proteins | 2014 |
Development and Evaluation of Artesunate-Loaded Chitosan-Coated Lipid Nanocapsule as a Potential Drug Delivery System Against Breast Cancer.
Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Artesunate; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Drug Stability; Excipients; Female; Humans; Lipids; MCF-7 Cells; Nanocapsules; Nanoparticles; Particle Size; Polymers | 2015 |
Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Artemisinins; Artesunate; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; MCF-7 Cells; MicroRNAs; Tumor Suppressor Protein p53 | 2016 |
Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers.
Topics: Apoptosis; Artemisinins; Artesunate; Breast Neoplasms; Female; Humans; Liposomes; MCF-7 Cells | 2016 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lenalidomide; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide; Tumor Cells, Cultured | 2011 |
Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production.
Topics: Antimalarials; Apoptosis; Artemisinins; Artesunate; Breast Neoplasms; Cell Line, Tumor; Chloroquine; Enzyme Inhibitors; Female; Humans; Iron; Lysosomes; Macrolides; Mitochondria; Mitochondrial Membranes; Permeability; Reactive Oxygen Species | 2011 |
Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.
Topics: Animals; Apoptosis; Artemisinins; Artesunate; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Humans; Matrix Metalloproteinase 1; Mice; Mice, Nude; NF-kappa B; Transcription Factor AP-1; Xenograft Model Antitumor Assays | 2011 |